The Cross-Party Group (CPG) on Brain Tumours, for which Brain Tumour Research provides the secretariat, held its first meeting of 2025, on Thursday 20ᵗʰ February, bringing together experts to discuss some of the pressing challenges for the brain tumour community in Scotland.
Professor Anthony Chalmers, Chair of Clinical Oncology at the University of Glasgow and Co-Director of the Scottish Brain Tumour Research Centre of Excellence, opened the discussion by addressing the difficulties in treating glioblastoma, one of the most aggressive forms of brain cancer.
Prof Chalmers highlighted the chronic underfunding of brain tumour research, describing it as a "high-risk, low-reward" area that struggles to attract commercial investment: "Despite the devastating impact of brain tumours, research funding remains disproportionately low compared to other cancers."
The discussion then turned to Proton Beam Therapy (PBT), an advanced form of radiotherapy that targets tumours more precisely than traditional methods, minimising damage to healthy brain tissue. Prof Chalmers noted that while PBT offers significant benefits, particularly in preserving cognitive function, access remains limited. Both UK hospitals offering PBT are located in England, forcing Scottish patients to travel long distances for treatment.
Liam Mac Lua-Hodgson, representing the Brain Tumour Charity, emphasised the importance of early diagnosis in improving patient outcomes: "Faster diagnosis not only enhances quality of life but also prevents disability and improves tolerance to treatment." However, he noted that brain tumours are notoriously difficult to diagnose due to their vague and non-specific symptoms.
Alastair Ross, Head of Public Policy at the Association of British Insurers, addressed the challenges faced by patients holidaying abroad. Mr Ross advised patients to seek specialist travel insurance providers rather than mainstream insurers, as costs are based on risk assessments that include destination and healthcare expenses: "Specialist providers are better equipped to cater to the unique needs of patients travelling for medical treatment."
Thomas Brayford, our Policy and Public Affairs Manager said: “As the CPG on Brain Tumours continues its work in 2025, the voices of patients, clinicians, researchers and advocates will remain at the forefront of efforts to drive change and improve outcomes for those affected by this devastating disease.”
Related reading:
Published Friday 21ˢᵗ February 2025.